Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicalgorithmics's revenue for the
three
months ended in Mar. 2026 was zł10.23 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was zł34.45 Mil.
Medicalgorithmics's Revenue per Share for the
three
months ended in Mar. 2026 was zł1.03.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł3.46.
Warning Sign:
Medicalgorithmics SA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Medicalgorithmics was 45.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -34.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -37.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -24.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Medicalgorithmics's highest 3-Year average Revenue per Share Growth Rate was 97.70% per year. The lowest was -54.00% per year. And the median was -21.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Medicalgorithmics Revenue Related Terms
Medicalgorithmics Revenue Historical Data
* Premium members only.
The historical data trend for Medicalgorithmics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medicalgorithmics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicalgorithmics Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medicalgorithmics's Revenue distribution charts can be found below:
* The bar in red indicates where Medicalgorithmics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł34.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicalgorithmics (WAR:MDG) has a Revenue of zł34.45 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Medicalgorithmics and its competitors.
Is Medicalgorithmics' Revenue too high?
Medicalgorithmics' current Revenue is zł34.45 Mil. Overall, Medicalgorithmics has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medicalgorithmics' Revenue compare to ABT and SYK?
Medicalgorithmics' Revenue of zł34.45 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Medicalgorithmics and its competitors. Medicalgorithmics's current Revenue is zł34.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicalgorithmics stock overvalued right now?
Based on GuruFocus' analysis, Medicalgorithmics (WAR:MDG) is currently considered Fairly Valued. The stock's GF Value™ is zł27.81, compared to a current price of zł27.85 — trading 0.1% above its estimated fair value. The current Revenue is zł34.45 Mil. Medicalgorithmics' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Medicalgorithmics (WAR:MDG), the current Revenue is zł34.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicalgorithmics (WAR:MDG) Overvalued in 2026?
Based on GuruFocus' analysis, Medicalgorithmics stock appears to be overvalued.
The current stock price of zł27.85 is trading 0.1% above its estimated GF Value™ of zł27.81.
GuruFocus considers Medicalgorithmics to be Fairly Valued.
Key valuation signals for WAR:MDG:
Revenue: zł34.45 Mil
GF Value™: zł27.81 vs. price of zł27.85 (0.1% above fair value)
No single metric tells the full story. See the WAR:MDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicalgorithmics SA is a medical technology company. It is engaged in the development of Digital Signal Processing (DSP) algorithms development and software and hardware electronics design for medical applications. The company specializes in providing advance technological solutions in the field of cardiac diagnostics, with a particular focus on ECG signal analysis. The group concentrates on the production and development of its flagship product Pocket ECG - a system for remote monitoring of cardiac arrhythmias. The offered solutions include algorithms and diagnostic systems used in remote heart monitoring. The company operates in Poland, the USA, and other, with majority of revenue from the USA.
72GF Score
Get the complete analysis for WAR:MDG
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDG has been successfully added to your 
